114088-58-3Relevant articles and documents
Human N6-methyl-AMP/dAMP aminohydrolase (abacavir 5-monophosphate deaminase) is capable of metabolizing N6-substituted purine acyclic nucleoside phosphonates
Schinkmanova, Marketa,Votruba, Ivan,Shibata, Riri,Han, Bin,Liu, Xiaohong,Cihlar, Tomas,Holy, Antonin
, p. 275 - 291 (2008)
Recombinant human abacavir monophosphate deaminase (hABC-MP deaminase) was compared with the recently described rat N6-methyl-AMP (meAMP) aminohydrolase. hABC-MP deaminase, a 42 kDa polypeptide, exists predominantly as a monomer under non-denaturing conditions. Similar to the rat enzyme, hABC-MP deaminase efficiently catalyzes the hydrolytic deamination of natural substrates meAMP (5), N6,N6-dimethyl-AMP (13) and medAMP (6). Acyclic nucleoside phosphonate (ANP) N6-cyclopropyl-2,6-diamino-9-[2- (phosphonomethoxy)ethyl]purine (cPrPMEDAP) (1), an intermediate intracellular metabolite of antileukemic agent GS-9219, was effectively converted to the corresponding active guanine analog by hABC-MP deaminase. In addition to cPrPMEDAP (1), a number of other biologically active N6-substituted purine ANPs are alternative substrates for hABC-MP deaminase. The efficiency of their deamination depends on the character of N6-substitution in the adenine and/or 2,6-diaminopurine ring. ANPs with N6-cyclic substituents are deaminated more readily than corresponding compounds with aliphatic substituents of the same length. The deamination of ANPs is also influenced by modifications at the phosphonoalkyl side chain. Among 9-[2-(phosphonomethoxy)propyl] ANPs, (S)-enantiomers are preferred to (R)-enantiomers. Alternatively, the presence of extended 9-[2-(phosphonoethoxy) ethyl] moiety leads to a moderate increase in the reaction velocity compared to cPrPMEDAP (1). Comparison of hABC-MP deaminase and the rat meAMP aminohydrolase across a broad spectrum of N6-substituted substrates revealed a strong correlation of their substrate specificities. Similar to the rat meAMP aminohydrolase, hABC-MP deaminase was highly sensitive to deoxycoformycin monophosphate, but not to the guanine product of cPrPMEDAP (1) deamination. Together, these data demonstrate that hABC-MP deaminase is human meAMP aminohydrolase involved in the intracellular activation of biologically active N6-substituted nucleotide analogs.
8-Aza-analogues of PMEA and PMEG: Synthesis and in vitro anti-HIV activity
Franchetti,Abu Sheikha,Cappellacci,Messini,Grifantini,Loi,De Montis,Spiga,La Colla
, p. 1707 - 1719 (1994)
8-Aza-analogues of the potent antiviral nucleotide analogues 9-[2- (phosphonomethoxy)ethyl]adenine (PMEA) and 9-[2- (phosphonomethoxy)ethyl]guanine (PMEG) were prepared and evaluated for activity against human immunodeficiency viruses. When compared to the parent compounds, 8-aza-PMEA (1) and -PMEG (2) were less cytotoxic for MT-4 cells, but also less potent against HIV-1 and HIV-2. A new synthesis of PMEG starting from guanine is also reported.
NUCLEOTIDE ANALOGS
-
, (2017/04/11)
Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
NUCLEOTIDE ANALOGS
-
, (2016/04/09)
Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection. In one embodiment, the invention describes compounds with antiviral activity against a papillomavirus in the absence of a significant antiproliferative host cell effect. Therefore, the invention includes antiviral agents that selectively inhibit and/or block viral DNA synthesis and/or the production of virions of high risk HPV types.
Microwave-assisted hydrolysis of phosphonate diesters: An efficient protocol for the preparation of phosphonic acids
Jansa, Petr,Baszczynski, Ondrej,Prochazkova, Eliska,Dracinsky, Martin,Janeba, Zlatko
supporting information; experimental part, p. 2282 - 2288 (2012/09/08)
A new highly efficient method for the hydrolysis of acyclic nucleoside phosphonate diesters (or generally of any organophosphonates) to the corresponding phosphonic acids has been developed. This novel methodology employs inexpensive hydrochloric acid in equimolar amounts to the number of ester groups present in the molecule and thus, avoids using trimethylsilyl halogenides, the standard reagents for these types of transformations. Moreover, simple and easy work-up of the reaction mixture affords very clean products in high yields (usually 77-93%). Another advantage of the described hydrolysis of phosphonate diesters is the fact that the course of the reaction can be instantly monitored through pressure changes in the reaction vessel. This 'green' method has also been successfully used for the preparation of otherwise synthetically difficult to access (phosphonomethoxy)ethyl (PME) derivatives of guanine (PMEG) and hypoxanthine (PMEHx), and furthermore, the method gains access to important novel acyclic nucleoside phosphonates derived from 2-chlorohypoxanthine and from xanthine (e.g. PMEX).
The preparation of 3H-labeled acyclic nucleoside phosphonates and study of their stability
Elbert, Tomas,Brehova, Petra,Holy, Antonin
experimental part, p. 757 - 766 (2011/05/12)
9-(2-Phosphonomethoxyethyl)-2,6-diamino-[8-3H]purine (4), 9-(2-phosphonomethoxyethyl)- [8-3H]guanine (6) and (R)-9-(2-phosphonomethoxypropyl)-[8-3H]adenine (11) with specific activities of 10.9, 7.9 and 16 Ci/mmol, respectively, were prepared by a catalytic dehalogenation of the corresponding 8-bromo derivatives 1, 2 and 9. The rate of the exchange of the tritium label on C-8 of the purine ring in title compounds with the hydrogen of water under physiological pH at 20 °C was studied using 3H NMR. The loss of 3H-label attained 7% in [8-3H]tenofovir (11), 10% in [8-3H]PMEDAP (4) and 12% in [8-3H]PMEG (6) after the period of 3 weeks. Storage at a temperature of -196 °C in liquid nitrogen ensured a better than 97% radiochemical purity of the prepared labeled compounds even after a six-month period.
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base
Holy, Antonín,Günter, Jaroslav,Dvo?áková, Hana,Masojídková, Milena,Andrei, Graciela,Snoeck, Robert,Balzarini, Jan,De Clercq, Erik
, p. 2064 - 2086 (2007/10/03)
A series of dialkyl esters of purine and pyrimidine N-[2- (phosphonomethoxy)ethyl] derivatives substituted at position 2, 6, or 8 of the purine base or position 2, 4, or 5 of the pyrimidine base were prepared by alkylation of the appropriate heterocyclic base with 2- chloroethoxymethylphosphonate diester in the presence of sodium hydride, cesium carbonate, or 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU) in dimethylformamide. Additional derivatives were obtained by the transformations of the bases in the suitably modified intermediates bearing reactive functions at the base moiety. The diesters were converted to the corresponding monoesters by sodium azide treatment, while the free acids were obtained from the diester by successive treatment with bromotrimethylsilane and hydrolysis. None of the PME derivatives in the pyrimidine series, their 6-aza or 3-deaza analogues, exhibited any activity against DNA viruses or retroviruses tested, except for the 5-bromocytosine derivative. Substitution of the adenine ring in PMEA at position 2 by Cl, F, or OH group decreased the activity against all DNA viruses tested. PMEDAP was highly active against HSV-1, HSV-2, and VZV in the concentration range (EC50) of 0.07-2 μg/mL. Also the 2-amino-6-chloropurine derivative was strongly active (EC50 = 0.1- 0.4 μg/mL) against herpes simplex viruses and (EC50 = 0.006-0.3 μg/mL) against CMV and VZV. PMEG was the most active compound of the whole series against DNA viruses (EC50 ~0.01-0.02 μg/mL), though it exhibited significant toxicity against the host cells. The base-modified compounds did not show any appreciable activity against DNA viruses except for 7-deazaPMEA (IC50 ~7.5 μg/mL) against HIV-1 and MSV. The neutral (diisopropyl, diisooctyl) diesters of PMEA were active against CMV and VZV, while the corresponding monoesters were inactive. The diisopropyl ester of the 2- chloroadenine analogue of PMEA showed substantially (10-100x) higher activity against CMV and VZV than the parent phosphonate. Also, the diisopropyl and diisooctyl ester of PMEDAP inhibited CMV and VZV, but esterification of the phosphonate residue did not improve the activity against either MSV or HIV.
Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
-
, (2008/06/13)
A series of compounds of Formula I which have anti-tumor activity, and are useful in treating viral infections, their compositions and use. STR1 In Formula I B is a purine or pyrimidine base; alk1 alk2 and alk3 are chemical bonds or alkylene groups; Q is hydrogen or hydroxyl; and R1 -R4 are hydrogen or alkyl.
Synthesis and antiviral activity of methyl derivatives of 9-[2- (phosphonomethoxy)ethyl]guanine
Yu,Bronson,Yang,Patick,Alam,Brankovan,Datema,Hitchcock,Martin
, p. 2958 - 2969 (2007/10/02)
A number of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG, 1) have been synthesized and tested in vitro for anti-herpes and anti- human immunodeficiency virus (HIV) activity. Among these analogues, (R)-2'- methyl-PMEG [(R)-3] and 2',2'-
